1. Pink Sheet
  2. >>R&D

Gene Therapy For Severe Retinitis Pigmentosa Secures EMA PRIME Status

 
• By Neena Brizmohun

Janssen and MeiraGTx say their investigational product is the only treatment for x-linked retinitis pigmentosa in development to win a place on the European Medicines Agency’s priority medicines scheme.

Eye_DNA
The most frequent mutation causing x-linked retinitis pigmentosa is in the RPGR gene • Source: Shutterstock

The European Medicines Agency has awarded Janssen and MeiraGTx priority medicines (PRIME) designation for the gene therapy they are co-developing to treat the most severe form of retinitis pigmentosa.

AAV-RPGR, for the treatment of x-linked retinitis pigmentosa (XLRP), is the latest investigational product to win a place on the PRIME scheme, which is designed to help

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Pink Sheet for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from R&D

More from Pink Sheet

EU Shaping Biotech Act To Unleash SME Potential

 
• By Neena Brizmohun

European companies, in particular small and midsize enterprises, spin-offs and start-ups have a hard time expanding within the single market “because of a complex regulatory framework that is perceived as slow and burdensome,” according to the European Commission.

New EU Filings

 
• By Neena Brizmohun

Brensocatib, Insmed's investigational treatment for non-cystic fibrosis bronchiectasis, is among the latest products that have been filed for review by the European Medicines Agency for potential EU marketing approval.

‘Tectonic’ Arkansas PBM Legislation May Upend Industry

 
• By Tim Casey

Industry will fight hard to prevent other states or the federal government from adopting measures similar to Arkansas' law preventing PBMs from owning pharmacies.